Biobide –Bionaturis Group- shows the advantages of zebrafish as animal model in three international events this November. The first one is the VIII Spanish Drug Discovery Network Meeting, which will be held on 3-4th November in Santiago de Compostela; the sencond one is the SETAC World Congress (on 6-10th November in Orlando, USA); and the third one is the World Preclinical Congress Europe in Lisbon on 14-16th.

This VIII Spanish Drug Discovery Network Meeting will be focused on the use of more predictive model systems throughout the discovery process, from early primary screening and moving towards preclinical and clinical studies. Among the main topics, they will tackle the  progress towards more predictive animal models both from an efficacy and safety perspective, two of the main assays that Biobide is specialized in using zebrafish as animal model. The General Manager of Biobide, Andoni Cruz, is the delegate in this meeting.

For further information about the VIII Spanish Drug Discovery Network Meeting, please, visit this website

The SETAC World Congress 2016 is one of the most relevant event worldwide in the Environmental Toxicology and Chemistry area. Biobide’s delegates -the R&D Management Director, Arantza Muriana, and the Study Director, Ainhoa Alzualde -will assist customers in the booth 814 in this edition in Orlando (USA). In addition, the company specialized in zebrafish belonged to Bionaturis Group, that has also presence in the USA with its subsidiary in the State of Maryland, will present the poster titled “Testing toxicity of graphene oxide in zebrafish embryos” next November, 8th, at 8.00 AM (13.00 in Spain).

For further information about the SETAC World Congress in Orlando, please, visit its official website ttps://

The World Preclinical Congress Europe is also very interesting for Biobide because it gathers every agent implied in the preclinical research and drug discovery in Europe. Its programme includes, among others, sessions leaded to ‘Optimizing leads and Predicting Drug Toxicity’, the Cambridge Healthtech Institute’s inaugural conference. The type of assays and models, the reliability of the data and how to translate them to the decision-making are some of the main topics of these sessions. In this occasion, Biobide’s delegate in Lisbon is the Business Development Manager, Maitane Ipiñazar.

For further information about the World Preclinical Congress Europe, please, visit its official website

About Biobide and Bionaturis Group

Biobide’s aim is to accelerate R&D process for Pharma, Biotech, Chemical, Cosmetic and Nutraceutical companies minimizing risks through our zebrafish services, adding value to clients R&D&i mainly in preclinical area.

To contact to Biobide

Bionaturis Group offers premiums solutions for human and animal health and currently comprises four companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific) and two subsidiaries (Biobide USA and BNT China Biosciences) in six different locations around the world. Bionaturis is listed on the Spanish stock exchange for SMEs (trading code BNT).